Company profile: Element Biosciences
1.1 - Company Overview
Company description
- Provider of innovative genetic analysis tools, including the AVITI System benchtop sequencer with dual flow cell capacity; AVITI24 integrating sequencing and Teton CytoProfiling to analyze DNA, RNA, proteins, and cell morphology from a single sample; Teton Assays targeting oncology, immunology, neuroscience; Cloudbreak Freestyle Kits to streamline AVITI workflows; and Avidity Sequencing for highly accurate, efficient data.
Products and services
- Avidity Sequencing: Leverages proprietary avidities to deliver highly accurate sequencing data more efficiently in a compact benchtop design
- AVITI System: A benchtop sequencer engineered for a wide range of sequencing experiments, enabling cost-effective, high-quality runs with dual flow cell capacity
- AVITI24: An integrated platform combining sequencing and Teton CytoProfiling, simultaneously analyzing DNA, RNA, proteins, and cell morphology from a single sample
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Element Biosciences
Carterra
HQ: United States
Website
- Description: Provider of biotechnology solutions for micro-array deposition technologies, delivering instruments and services that enable multiplexing on planar array surfaces. Offerings include LSA and LSAXT for monoclonal antibody characterization (kinetics, epitope binning), Continuous Flow Microspotter (CFM), sensor chips, kinetics and epitope software, and AI/ML in silico tools for drug discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Carterra company profile →
Polyplus Transfection
HQ: France
Website
- Description: Provider of innovative solutions for in vivo, in vitro and ex vivo delivery of nucleic acids for research, bioproduction and therapeutics, including transfection reagents for lentiviral (FectoVIR®-LV) and AAV production (FectoVIR®-AAV), PEIpro® for viral vector bioproduction, in vivo–jetPEI®, LipidBrick® Library for LNP formulation, and in vivo-jetRNA®+ for mRNA/saRNA delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Polyplus Transfection company profile →
Altucell
HQ: United States
Website
- Description: Provider of cell, molecular, and regenerative therapy for treating diabetes, addressing an unmet need.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Altucell company profile →
Elegen
HQ: United States
Website
- Description: Provider of cell-free DNA synthesis solutions, including ENFINIA DNA producing long, complex linear DNA up to 7kb with 99.999% per-base accuracy, shipped in 6 to 8 business days; high-complexity DNA synthesis for challenging sequences like long repeats and GC-rich regions, with delivery as fast as 10 business days; and an Early Access Program for pre-commercial products, including sequences longer than 15,000 base pairs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elegen company profile →
StemoniX
HQ: United States
Website
- Description: Provider of stem cell–based, human-relevant in vitro platforms for drug discovery and toxicity testing. Products include NerveSim (3D peripheral nervous system model with nerve conduction and neurodegeneration metrics), BrainSim (3D brain organoid platform), and microBrain (human iPSC-derived CNS screening with functional cortical neuron–astrocyte networks). Founded in 2014, headquartered in Maple Grove, Minnesota.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full StemoniX company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Element Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Element Biosciences
2.2 - Growth funds investing in similar companies to Element Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Element Biosciences
4.2 - Public trading comparable groups for Element Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →